Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Nanomaterial Definition Brings Measurement Challenges

This article was originally published in The Tan Sheet

Executive Summary

The European Commission’s definition of “nanomaterial,” to potentially be used in legislation, appears to be relatively simple. In practice, measuring particles against the standard offers a number of technological challenges.

You may also be interested in...



In Nanotech Metrics, Safety Should Trump Size, Experts Say

Presenters at the FDLI annual conference say evaluations of novel health care and consumer products based on nanotechnology should focus on safety and efficacy more than particle size. The Project on Emerging Nanotechnologies is updating its product inventory to include nanomaterial safety data.

In Nanotech Metrics, Safety Should Trump Size, Experts Say

Presenters at the FDLI annual conference say evaluations of novel health care and consumer products based on nanotechnology should focus on safety and efficacy more than particle size. The Project on Emerging Nanotechnologies is updating its product inventory to include nanomaterial safety data.

FDA Advisors Want More Data On Nanotech Sunscreens

Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s knowledge of pharmaceutical firms’ use of nanotechnology still is developing, but maintain the products are safe.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel